Literature DB >> 35064846

Changes in left atrial appendage orifice following percutaneous left atrial appendage closure using three-dimensional echocardiography.

Xochitl A Ortiz-Leon1,2, Edith L Posada-Martinez1,2, Alda Bregasi1,3, Wanwen Chen1, Ian Crandall1, Jason Pereira1, Kamil F Faridi1, Joseph G Akar1, Ben A Lin1,3, Robert L McNamara1, James V Freeman1, Jeptha Curtis1, Jose A Arias-Godinez2, Lissa Sugeng4.   

Abstract

Percutaneous left atrial appendage (LAA) occlusion is increasingly performed in patients with atrial fibrillation and long-term contraindications for anticoagulation. Our aim was to evaluate the effects of LAA occlusion with the Watchman device on the geometry of the LAA orifice and assess its impact on the adjacent left upper pulmonary vein (LUPV) hemodynamics. We included 50 patients who underwent percutaneous LAA occlusion with the Watchman device and had acceptable three-dimensional transesophageal echocardiography images of LAA pre- and post-device placement. We measured offline the LAA orifice diameters in the long axis, and the minimum and maximum diameters, circumference, and area in the short axis view. Eccentricity index was calculated as maximum/minimum diameter ratio. The LUPV peak S and D velocities pre- and post-procedure were also measured. Patients were elderly (mean age 76 ± 8 years), 30 (60%) were men. There was a significant increase of all LAA orifice dimensions following LAA occlusion: diameter 1 (pre-device 18.1 ± 3.2 vs. post-device 21.5 ± 3.4 mm, p < 0.001), diameter 2 (20.6 ± 3.9 vs. 22.1 ± 3.6 mm, p < 0.001), minimum diameter (17.6 ± 3.1 vs. 21.3 ± 3.4 mm, p < 0.001), maximum diameter (21.5 ± 3.9 vs. 22.4 ± 3.6 mm, p = 0.022), circumference (63.6 ± 10.7 vs. 69.6 ± 10.5 mm, p < 0.001), and area (3.1 ± 1.1 vs. 3.9 ± 1.2 cm2, p < 0.001). Eccentricity index decreased after procedure (1.23 ± 0.16 vs. 1.06 ± 0.06, p < 0.001). LUPV peak S and D velocities did not show a significant difference (0.29 ± 0.15 vs. 0.30 ± 0.14 cm/s, p = 0.637; and 0.47 ± 0.19 vs. 0.48 ± 0.20 cm/s, p = 0.549; respectively). LAA orifice stretches significantly and it becomes more circular following LAA occlusion without causing a significant impact on the LUPV hemodynamics.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Atrial fibrillation; Left atrial appendage occlusion; Three-dimensional echocardiography; Watchman device

Year:  2022        PMID: 35064846     DOI: 10.1007/s10554-022-02525-y

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  26 in total

1.  Death from pulmonary artery erosion complicating implantation of percutaneous left atrial appendage occlusion device.

Authors:  Ali Sepahpour; Martin K C Ng; Philip Storey; Mark A McGuire
Journal:  Heart Rhythm       Date:  2013-07-31       Impact factor: 6.343

2.  2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Hugh Calkins; Lin Y Chen; Joaquin E Cigarroa; Joseph C Cleveland; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Karen L Furie; Paul A Heidenreich; Katherine T Murray; Julie B Shea; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2019-01-28       Impact factor: 24.094

3.  Pulmonary artery perforation caused by a left atrial appendage closure device.

Authors:  Cong Lu; Jie Zeng; Qingguo Meng; Zhi Zeng
Journal:  Catheter Cardiovasc Interv       Date:  2019-10-17       Impact factor: 2.692

Review 4.  Left atrial appendage exclusion for stroke prevention in patients with nonrheumatic atrial fibrillation.

Authors:  Orhan Onalan; Eugene Crystal
Journal:  Stroke       Date:  2007-02       Impact factor: 7.914

5.  Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.

Authors:  David R Holmes; Saibal Kar; Matthew J Price; Brian Whisenant; Horst Sievert; Shephal K Doshi; Kenneth Huber; Vivek Y Reddy
Journal:  J Am Coll Cardiol       Date:  2014-07-08       Impact factor: 24.094

Review 6.  Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation.

Authors:  J L Blackshear; J A Odell
Journal:  Ann Thorac Surg       Date:  1996-02       Impact factor: 4.330

7.  Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.

Authors:  David R Holmes; Vivek Y Reddy; Zoltan G Turi; Shephal K Doshi; Horst Sievert; Maurice Buchbinder; Christopher M Mullin; Peter Sick
Journal:  Lancet       Date:  2009-08-15       Impact factor: 79.321

8.  The NCDR Left Atrial Appendage Occlusion Registry.

Authors:  James V Freeman; Paul Varosy; Matthew J Price; David Slotwiner; Fred M Kusumoto; Chidambaram Rammohan; Clifford J Kavinsky; Zoltan G Turi; Joseph Akar; Cristina Koutras; Jeptha P Curtis; Frederick A Masoudi
Journal:  J Am Coll Cardiol       Date:  2020-04-07       Impact factor: 24.094

9.  Left circumflex coronary artery occlusion due to a left atrial appendage closure device.

Authors:  András Katona; András Temesvári; András Szatmári; Attila Nemes; Tamás Forster; Géza Fontos
Journal:  Postepy Kardiol Interwencyjnej       Date:  2015-03-06       Impact factor: 1.426

10.  Pulmonary vein compression after implantation of a left atrial appendage occluder: presentation and discussion of a case.

Authors:  Maryam Ayati; Feifan Ouyang; Kh Kuck
Journal:  Indian Pacing Electrophysiol J       Date:  2014-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.